Document Detail

Recombinant high-density lipoprotein formulations.
MedLine Citation:
PMID:  21057986     Owner:  NLM     Status:  In-Process    
High-density lipoprotein cholesterol (HDL-C) has emerged as a biomarker of residual cardiovascular disease (CVD) risk in high-risk patients treated with low-density lipoprotein cholesterol (LDL-C)-lowering therapies inclusive of inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA reductase. The evidence for increasing low levels of HDL-C is sparse, and the available data are confounded by metabolic interactions between elevated very low-density lipoprotein (VLDL) and LDL particle concentrations. Despite these limitations, there has been widespread interest in novel strategies that target HDL. One such path has been the development of recombinant HDL formulations that mimic the pre-beta fraction of native HDL, which is the main HDL subclass that mediates cholesterol efflux from lipid-laden macrophages. Various recombinant HDL formulations (apolipoprotein A-1 [apoA-1]-bound phospholipid disks or delipidated HDL particles, mutant apoA-1 proteins, and apoA-1 mimetic peptides) have been investigated in animal studies and some human trials. However, these HDL-modifying therapies require evaluation in clinical trials of atherosclerosis and CVD events. This review presents our current knowledge on novel recombinant therapies, and their future prospects to mitigate atherosclerotic CVD events.
Esad Vucic; Robert S Rosenson
Related Documents :
7138616 - In vitro reciprocal exchange of apoproteins and nonpolar lipids between human high dens...
19029466 - Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and pr...
10938016 - Short-term feeding of atherogenic diet to mice results in reduction of hdl and paraoxon...
10393206 - Metabolic and genetic determinants of hdl metabolism and hepatic lipase activity in nor...
2592686 - A comparison of the validity of three scales for the assessment of dietary restraint.
24788396 - The effect of exposure to a high-fat diet on microrna expression in the liver of blunt ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current atherosclerosis reports     Volume:  13     ISSN:  1534-6242     ISO Abbreviation:  Curr Atheroscler Rep     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897685     Medline TA:  Curr Atheroscler Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  81-7     Citation Subset:  IM    
Translational and Molecular Imaging Institute, Imaging Science Laboratories, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Age estimation and the medial clavicular epiphysis: analysis of the age of majority in an Australian...
Next Document:  Markers of thrombin generation during resurfacing and noncemented total hip arthroplasty: a pilot st...